Parabilis Medicines, Inc.
No enriched coverage for $PBLS in the last 7 days.
No SEC Form 4 filings for $PBLS in the last 30 days.
See all $PBLS insider activity →MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Office
Recent PBLS coverage spans market movers, corporate actions and insider activity.
Post‑IPO momentum and recent FDA designations lifted the stock.
Speculative move.
The CMO exit may cause short-term uncertainty but limited long-term impact.
Board addition may strengthen oncology expertise and support pipeline progress.
Post-IPO capital and favorable FDA designations can improve perceived probability of clinical success, supporting speculative demand.
AlphAI scores every news story that mentions PBLS with an AI model for sentiment and relevance, and aggregates insider trades from Parabilis Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
3 min readVicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Office
1 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors CAMBRIDGE, Mass., August 25, 2026 – Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for pat
1 min readBiotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
5 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research colla
5 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readRA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.
2 min readOn July 6, 2026, analyst actions included T-Mobile US (TMUS) upgraded to Buy by Bank of America with a $220 target, and Gilead Sciences (GILD) upgraded to Buy by HSBC with a $155 target. Datadog (DDOG) was downgraded to Market Perform by Bernstein; HSBC cut Pfizer (PFE) to Hold. The article also cites mixed rates, gold up ~2%, and Bitcoin above $61,000.
5 min readLevy Guy purchased 500,000 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($10.00M total) across 2 trades on 2026-06-11.
2 min read